Anti-Cancer Medicines Availability: International Study
Study objectives: to provide health authorities with data on the availability of licensed anti-neoplastic medicines
International Article
The ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe was published in Annals of Oncology in September 2017 to view the article please select below:
Preliminary findings presented during ECC 2015 and ESMO Asia 2015
N. Cherny presented the preliminary data from the international arm of the study during the ESMO Society Session at ECC 2015, while A. Eniu presented the study during an ESMO Asia 2015 Special Session: Resource constraints as a barrier to lung cancer management: Developing nations.
Watch N. Cherny's presentation from ECC 2015
Watch A. Eniu's presentation from ESMO Asia 2015
Study objectives
The goals of this study are:
- to provide national health authorities with data on the availability of licensed anti-neoplastic medicines
- to report on the actual availability of anti-neoplastic medicines to patients when they are prescribed and when patients can afford them
- to provide data that health authorities can create policies to improve availability and patient access to medically necessary cancer therapies
- because no such data currently exists, this study intends to map out the situation, particularly in view of:
- Recent medicine shortages due to the unavailability in several countries of some common, affordable, medically necessary anti-cancer medicines
- Barriers to access to new, expensive medicines due to limited resources available in some countries
Coordinating partners
This ESMO study is conducted under the auspices of the ESMO Global Policy Committee (formerly ESMO Emerging Countries Committee) in collaboration with the:
- Kings College London Institute of Cancer Policy
- European Society of Oncology Pharmacy (ESOP - liaising with the International Society of Oncology Pharmacy Practitioners (ISOPP)).
- Union for International Cancer Control (UICC)
- World Health Organization (WHO)
Collaborating partners
- American Society of Clinical Oncology (ASCO)
- Chinese Society of Clinical Oncology (CSCO)
- Indian Society for Medical & Pediatric Oncology (ISMPO)
- Japanese Society of Medical Oncology (JSMO)
- Korean Society of Medical Oncology (KSMO)
- Myanmar Oncology Society (MOS)
- Medical Oncology Group of Australia Incorporated (MOGA)
- Medical Oncology Society of Peru (SPOM - Sociedad Peruana de Oncologia Médica)
- Middle East Cancer Consortium (MECC)
Collaborators
- African Organisation for Research and Training in Cancer (AORTIC)
- Latinamerican & Caribbean Society of Medical Oncology (SLACOM)
- ESMO National Representatives Committee